To elucidate how neuronal ensembles interactively encode higher brain processes, new and improved methods for both recording and manipulating neuronal activity will be required.^[@ref1],[@ref2]^ The ability to selectively modulate the activity of defined neuronal populations and to elucidate the behavioral consequences of this selective neuronal modulation affords powerful approaches for studying mammalian brain function in health and disease. Historically, important methods include Wilder Penfield's pioneering studies of focal electrical stimulation of the human cortex.^[@ref3]^ The development of the optogenetics technology pioneered by Diesseroth and colleagues to visualize and activate neuronal activity with exquisite temporal resolution using engineered channelrhodopsin^[@ref4],[@ref5]^ and other opsins^[@ref6]^ has provided an expanding toolbox for decoding the neuronal correlates of brain function.^[@ref4],[@ref6]−[@ref10]^ More recently, Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) have been developed as a powerful chemogenetics technology for remotely controlling neuronal activity^[@ref11],[@ref12]^ and have been widely adopted by the neuroscience and greater biological communities.^[@ref13]−[@ref18]^

DREADDs, first revealed in 2005,^[@ref5]^ were developed using directed molecular evolution of human muscarinic acetylcholine receptors.^[@ref11],[@ref12]^ After multiple rounds of random mutagenesis, DREADDs derived from the human muscarinic acetylcholine M3 receptors (hM3Dq) to be insensitive to the endogenous ligand acetylcholine (ACh) but potently and selectively activated by the pharmacologically inert clozapine *N*-oxide (CNO) were discovered. Importantly, CNO lacks appreciable affinity (*K*~i~ \> 1 μM) for all relevant native CNS (central nervous system) targets.^[@ref11],[@ref19]^ The DREADDs have no detectable constitutive activity in vitro^[@ref11]^ and, thus, provide an attractive orthologous receptor-effector chemogenetic platform for modifying neuronal activity remotely with minimal invasiveness. In addition to hM3Dq, which activates neuronal firing upon the CNO stimulation in part by depolarization and elevation of intracellular calcium levels,^[@ref12]^ hM4Di was developed from human muscarinic acetylcholine M4 receptors for inhibiting neuronal firing via activation of G-protein inwardly rectifying potassium (GIRK) channels.^[@ref11]^ Since the introduction of the DREADD technology, a large number of papers have independently validated the utility of excitatory and inhibitory DREADDs.^[@ref12],[@ref21]−[@ref34]^ In addition, no effect related to the ectopic expression of hM3Dq or hM4Di has been observed.

In addition to being pharmacologically inert, CNO, the "chemical switch" of this chemogenetic approach, is orally bioavailability and CNS penetrant^[@ref21],[@ref35]−[@ref37]^ and is not subject to significant metabolic transformation in mice and rats. However, a small fraction of CNO is apparently metabolized to clozapine in humans, nonhuman primates and guinea pigs.^[@ref36],[@ref39],[@ref41]^ Because clozapine modulates the activity of many native CNS receptors,^[@ref42]^ thus interfering with the selective activation of the DREADDs in defined neuronal populations, the "back-metabolism" issue presents a hurdle for translating the DREADD technology forward. To ultimately develop the next generation of DREADD ligands that can selectively activate defined neuronal populations in primates including human, a thorough understanding of structure--activity relationships (SARs) of DREADDs is needed. To date, no SAR studies have been reported for any DREADDs including hM3Dq and hM4Di.

Here, we report the first SAR studies of hM3Dq. We extensively explored multiple regions of the scaffold represented by CNO, which resulted in the discovery of compounds **13** and **21** that are very potent hM3Dq agonists but do not activate the native human M3 receptor (hM3). We describe the design, synthesis, and pharmacological evaluation of new CNO analogues and discuss the interesting SAR trends revealed from the studies. We also report the discovery that perlapine, a hypnotic agent first reported in 1966,^[@ref43]−[@ref45]^ is a novel, potent, and selective agonist of hM3Dq (\>10 000-fold selective for hM3Dq over hM3).

Results and Discussion {#sec2}
======================

Design and Synthesis {#sec2.1}
--------------------

To understand the SAR of CNO analogues as hM3Dq agonists, we explored several regions of the CNO scaffold. In particular, we focused on investigating the R^1^ and R^2^ substituents as well as modifications to the piperazine ring (highlighted in red in Figure [1](#fig1){ref-type="fig"}). We also studied whether the chloro group (R^3^, highlighted in blue in Figure [1](#fig1){ref-type="fig"}) on the tricyclic core is required and whether a different tricyclic core (e.g., the core of the perlapine scaffold, see below) can be tolerated.

![SAR studies of the CNO scaffold.](cn-2014-00325v_0001){#fig1}

We first explored the size of the alkyl group (R^1^) on the N4′ position of the CNO scaffold and synthesized a set of close analogues as outlined in Scheme [1](#sch1){ref-type="scheme"}. The commercially available 2-((2-amino-4-chlorophenyl)amino)benzoic acid (**1**) was refluxed in xylene for 48 h to give the cyclized compound **2**, which was then treated with POCl~3~ and *N*,*N*-dimethylaniline in toluene at 95 °C for 2 h to afford the chloride **3**. Compound **3** was reacted with various *N*-alkylpiperazines in toluene at 120 °C for 2 h to yield compounds **4a**--**4d**, which were then converted to their corresponding *N*-oxides **5a**--**5d** by treating with *meta*-chloroperoxybenzoic acid (*m*CPBA) at room temperature in CH~2~Cl~2~ for 10 min. The synthetic route to compounds **4a** -- **4d** was described previously.^[@ref46],[@ref47]^

![Synthesis of N4′-alkyl Substituted CNO Analogues\
Reagents and conditions: (a) xylene, reflux, 48 h, 95% yield; (b) POCl~3~, *N*,*N*-dimethylaniline, toluene, 95 °C, 2 h, 67% yield; (c) *N*-alkylpiperazines, toluene, 120 °C, 2 h, 69--80% yield; and (d) *m*CPBA, CH~2~Cl~2~, rt, 10 min, 65--75% yield.](cn-2014-00325v_0004){#sch1}

We next synthesized the analogues outlined in Scheme [2](#sch2){ref-type="scheme"} to determine whether the positive charge of CNO is required for activating hM3Dq. For example, compound **6**, which contains a quaternary ammonium moiety, has a permanent positive charge, while compounds **7**, **9**, **12**, and **14** do not possess a basic amino group and therefore do not contain a positive charged group. As illustrated in Scheme [2](#sch2){ref-type="scheme"}, compound **4a** (clozapine) was converted to the quaternary ammonium iodide **6** by stirring overnight with CH~3~I in acetone at room temperature. Compound **3** was treated with piperazin-2-one at 99 °C overnight in the 1:1 mixture of 1,4-dioxane and ethanol to give compound **7**. Similarly, compound **9** was produced by treating compound **3** with commercially available 1,3,8-triazaspiro\[4.5\]decane-2,4-dione (**8**) in the 2:1 mixture of 1,4-dioxane and *N*,*N*-dimethylformamide (DMF) at 130 °C for 24 h. Hydrolysis of compound **9** using 0.5 N aqueous NaOH solution in 1,2-dimethoxyethane under microwave irradiation afforded compound **10**. Likewise, compound **11** was prepared from compound **3** and piperazine in toluene at 120 °C for 2 h. Acetylation of compound **11** by AcCl in CH~2~Cl~2~ at 0 °C in the presence of triethylamine (TEA) yielded compound **12**, which was subsequently reduced to the deuterated compound **13** using LiAlD~4~ under reflux conditions, followed by quenching with CD~3~OD at 0 °C. In addition, compound **11** was reacted with MsCl in CH~2~Cl~2~ at 0 °C in the presence of diisopropylethylamine (DIPEA) to give the methylsulfonamide **14**.

![Synthesis of Compounds **6**, **7**, and **9**--**14**\
Reagents and conditions: (a) CH~3~I, acetone, rt, overnight, 55% yield; (b) 2-oxypiperazine, 1,4-dioxane/ethanol 1:1, 99 °C, overnight, 65% yield; (c) 1,3,8-triazaspiro\[4.5\]decane-2,4-dione (**8**), 1,4-dioxane/DMF (2:1), 130 °C, 24 h, 66% yield; (d) 1,2-dimethoxyethane, 0.5 N NaOH, microwave, 150 °C, 10 min, 16% yield; (e) piperazine, toluene, 120 °C, 2 h, 69% yield; (f) AcCl, TEA, CH~2~Cl~2~, 0 °C, 1 h, 86% yield; (g) (1) LiAlD~4~, THF, N~2~, reflux, 2h, (2) CD~3~OD, 0 °C, (3) NH~4~OH, 0 °C, 84% yield; (h) MsCl, DIPEA, CH~2~Cl~2~, 0 °C, 1 h, 93% yield.](cn-2014-00325v_0005){#sch2}

To determine whether the 8-Cl group on the tricyclic core is required to activate hM3Dq, we prepared compounds **21**--**23** according to the synthetic route outlined in Scheme [3](#sch3){ref-type="scheme"}.^[@ref48]^ The commercially available 2-aminobenzoic acid (**15**) and 2-nitrophenyl iodide (**16**) were subjected to Ullmann coupling conditions^[@ref49]^ to afford the aniline **17**. Reduction of the nitro moiety of compound **17** yielded compound **18**, which was refluxed in xylene to generate the benzodiazepine **19**. Treatment of compound **19** with POCl~3~ provided the chloride **20**, which was then displaced with piperazine to afford compound **21**. Similarly, compound **22** was prepared by the displacement reaction of the chloride **20** with 1-ethylpiperazine in toluene under reflux conditions. In addition, the oxidation of compound **22** by *m*CPBA in CH~2~Cl~2~ afforded the *N*-oxide **23**.

![Synthesis of Compounds **22**--**24**\
Reagents and conditions: (a) K~2~CO~3,~ Cu, 3-methylbutan-1-ol, reflux, 4 h; (b) NaS~2~O~4~, NH~4~OH/H~2~O 3:2, 80 °C, 30 min, 75% yield in two steps; (c) xylene, reflux, Dean--Stark conditions, 48 h, 96% yield; (d) POCl~3~, *N*,*N*-dimethylaniline, toluene, reflux, 3 h, 52% yield; (e) piperazine, toluene, reflux, overnight, 63% yield; (f) 1-ethylpiperazine, toluene, reflux, 2 h, 72% yield; and (g) *m*CPBA, CH~2~Cl~2~, rt, 10 min, 78% yield.](cn-2014-00325v_0006){#sch3}

Biological Evaluation {#sec2.2}
---------------------

The newly synthesized compounds were evaluated in the hM3Dq and hM3 Ca^2+^ mobilization fluorometric imaging plate reader (FLIPR^TETRA^) assays according to the protocols reported previously.^[@ref11],[@ref50],[@ref51]^ Agonist activities of these compounds in the hM3Dq and hM3 functional assays are summarized in Table [1](#tbl1){ref-type="other"}.

###### Agonist Activities of New Compounds in hM3Dq and hM3 FLIPR Assays[a](#t1fn1){ref-type="table-fn"}

           hM3Dq      hM3              
  -------- ---------- ----- ---------- -----
  **4a**   1.1        95    360        88
  **4b**   7.0        91    \>30 000   NA
  **4c**   13         45    \>30 000   NA
  **4d**   71         50    \>30 000   NA
  **5a**   6.0        100   \>30 000   NA
  **5b**   19         50    \>30 000   NA
  **5c**   190        45    \>30 000   NA
  **5d**   740        79    \>30 000   NA
  **6**    0.069      100   9.5        92
  **7**    \>30 000   NA    \>30 000   NA
  **9**    \>30 000   NA    \>30 000   NA
  **10**   \>30 000   NA    \>30 000   NA
  **11**   2.1        95    490        86
  **12**   \>30 000   NA    \>30 000   NA
  **13**   9.6        86    \>30 000   NA
  **14**   \>30 000   NA    \>30 000   NA
  **21**   1.7        100   NA         ∼20
  **22**   1.3        81    \>30 000   NA
  **23**   220        59    \>30 000   NA

EC~50~ values are the average of at least two duplicate experiments with standard deviation (SD) values that are 3-fold less than the average. NA: not applicable.

For the size of the *N*-alkyl group in compounds **4a**--**4d** and **5a**--**5d**, we observed a clear trend showing that the longer and/or bulkier the *N*-alkyl group, the weaker the compounds' potency for hM3Dq. The replacement of the methyl group in compounds **4a** and **5a** with the *n*-propyl group in compounds **4d** and **5d** resulted in a potency decrease of approximately 70- and 100-fold, respectively. In addition to the loss in potency, the compounds with a longer or bulkier *N*-alkyl group (e.g., compounds **4b**--**4d** and **5b**--**5d**) in general displayed lower agonist efficacy for hM3Dq and became partial agonists of hM3Dq rather than full agonists as seen for compounds **4a** and **5a**. Interestingly, compounds **4c** and **5c**, which contain an *i*-propyl group, were more potent than compounds **4d** and **5d**, which contain a *n*-propyl group, suggesting that the length of the *N*-alkyl group plays a more significant role than the bulkiness of the *N*-alkyl group in reducing agonist potency. We were also pleased to find that compounds **4b**--**4d** and **5b**--**5d** did not display any agonist activity (EC~50~ \> 30 000 nM) for the native human M3 receptor (hM3), in contrast to compound **4a** (clozapine), which was a hM3 agonist with sub-μM potency. In addition, compounds **4a**--**4d** were in general more potent than their corresponding *N*-oxides **5a**--**5d** at activating hM3Dq, suggesting that the negative charge on the *N*-oxides is not only not required for activating hM3Dq, but also reduces agonist potency.

The quaternary ammonium salt **6** was an extremely potent full agonist of hM3Dq with an EC~50~ value of 69 pM and about 15-fold more potent than compound **4a** (clozapine). However, compound **6** was also a potent full agonist of hM3 (EC~50~ = 9.5 nM, *E*~max~ = 92) even though it achieves \>100-fold higher potency for hM3Dq over hM3. On the other hand, compounds **7**, **12**, and **14**, which do not contain a basic amino group or a group with permanent positive charge, did not display any agonist activity for hM3Dq. As expected, these compounds did not activate hM3 either. Taken together, these results suggest that either a basic amino group as in compounds **4a** and **4b** or a group with permanent positive charge as in compounds **5a** and **6** is required to retain hM3Dq agonist activity. In addition, compound **9** that contains a hydantoin moiety and compound **10** that contains an amino acid moiety in this region did not activate hM3Dq and hM3. On the other hand, compound **11**, which is the des-methyl clozapine, showed similar potency and efficacy for hM3Dq and hM3 as clozapine, suggesting that the *N*-methyl group is not required for activating hM3Dq. Interestingly, compound **13**, which is a deuterated analogue of compound **4b**, exhibited similar potency and efficacy (EC~50~ = 9.6 nM, *E*~max~ = 86%) for hM3Dq as compounds **4b** and **5a** (CNO) (Figure [2](#fig2){ref-type="fig"}). Importantly, compound **13** did not display any agonist activity for hM3. Because compound **13** contains an α,α-dideutero ethyl group, it is likely that the *N*-dealkylation, the major metabolic pathway that converts clozapine to des-methyl clozapine,^[@ref36],[@ref39]^ will be significantly reduced on the basis of the well-documented primary kinetic isotope effect^[@ref52]^ in similar systems.^[@ref53],[@ref54]^

![Compounds **13** and **21** are potent hM3Dq agonists and do not activate hM3 being similar to compound **5a** (CNO). The endogenous ligand acetylcholine (ACh), on the other hand, is a potent hM3 agonist and does not activate hM3Dq.](cn-2014-00325v_0002){#fig2}

We were also pleased to find that the 8-chloro group was not required to maintain high agonist potency and efficacy for hM3Dq. In particular, compound **21** was a potent full agonist (EC~50~ = 1.7 nM, *E*~max~ = 100%) of hM3Dq (Figure [2](#fig2){ref-type="fig"}). In contrast to compound **11**, a full hM3 agonist with sub-micromolar potency, compound **21** displayed little agonist activity for hM3 (*E*~max~ = ∼20%). In addition, compound **22** was found to be a potent hM3Dq agonist (EC~50~ = 1.3 nM, *E*~max~ = 81%), which was more potent than the corresponding chloro analogue, compound **4b** (EC~50~ = 7.0 nM, *E*~max~ = 91%). On the other hand, the *N*-oxide **23** (EC~50~ = 220 nM, *E*~max~ = 59%) was about 10-fold less potent for hM3Dq than compound **5b**, the corresponding chloro analog (EC~50~ = 19 nM, *E*~max~ = 50%). Similar to compound **21**, both compounds **22** and **23** did not exhibit any agonist activity for hM3.

We next selected a subset of the above hM3Dq agonists that are inactive against hM3 and assessed their binding affinities to other aminergic GPCRs. Because compound **4a** (clozapine) showed high binding affinities to 5HT~2A~ and 5HT~2C~ serotonin, α~1A~ adrenergic, and H~1~ histamine receptors with *K*~i~ values of 5.4, 9.4, 1.6, and 1.1 nM, respectively (Table [2](#tbl2){ref-type="other"}), we tested compounds **4b**, **4c**, **5b**, **5c**, **13**, and **21** in 5HT~2A~, 5HT~2C~, α~1A~, and H~1~ radioligand binding assays. The assay results are summarized in Table [2](#tbl2){ref-type="other"}.

###### Binding Affinities of Selected hM3Dq Agonists to Other GPCRs[a](#t2fn1){ref-type="table-fn"}

           *K*~i~ (nM)                     
  -------- ------------- ------ ---------- ------
  **4a**   5.4           9.4    1.6        1.1
  **4b**   29            24     46         1.9
  **4c**   16            17     37         4.6
  **5b**   1900          5100   \>10 000   160
  **5c**   5200          6700   320        6200
  **13**   71            280    67         5.0
  **21**   66            170    280        6.0

*K*~i~ values are the average of at least 2 duplicate experiments with standard deviation (SD) values that are 3-fold less than the average.

Compounds **4b** and **4c** had reduced binding affinities to 5HT~2A~, 5HT~2C~, and α~1A~ (*K*~i~ = 16--46 nM) compared with compound **4a** (clozapine), but retained high binding affinities to H~1~ (*K*~i~ \< 5.0 nM). On the other hand, the *N*-oxide **5b** displayed weak binding affinities for 5HT~2A~, 5HT~2C~, and α~1A~ (*K*~i~ \> 1000 nM) and was about 8-fold selective for hM3Dq over H~1~, while the *N*-oxide **5c** displayed poor binding affinities to 5HT~2A~, 5HT~2C~, and H~1~ (*K*~i~ \> 5000 nM) but was only about 2-fold selective for hM3Dq over α~1A~. Interestingly, compound **13**, a deuterated analogue of compound **4b**, exhibited reduced binding affinities to all four receptors compared with compound **4b**. Compound **13** was selective for hM3Dq over 5HT~2A~ (7-fold), 5HT~2C~ (29-fold), and α~1A~ (7-fold), but was not selective over H~1~. We were pleased to find that compound **21** displayed much improved selectivity compared with compound **4a** (clozapine). In addition to being inactive at hM3, compound **21**, a potent full agonist of hM3Dq (EC~50~ = 1.7 nM), was 40-fold selective over 5HT~2A~, 100-fold selective over 5HT~2C~, and 165-fold selective over α~1A~. Although it was only 3.5-fold selective for hM3Dq over H~1~, the overall selectivity profile of compound **21** is significantly better than compound **4a** (clozapine).

Lastly, to identify an alternative compound that might activate hM3Dq, we conducted a screen of the commercially available Library Of Pharmaceutically Active Compounds (LOPAC; *N* = 1280 compounds) and Prestwick Chemical Library (*N* = 1280 compounds) using the hM3Dq FLIPR assay. From this screen, we discovered perlapine as a novel, potent agonist of hM3Dq (Figure [3](#fig3){ref-type="fig"}). Importantly, perlapine was \>10 000-fold selective for hM3Dq over hM3. Interestingly, perlapine contains a different tricyclic core in comparison with CNO. The high hM3Dq potency of perlapine suggests that the benzodiazepine tricyclic core of the CNO (compound **5a**) scaffold is not required for maintaining high hM3Dq agonist activity.

![Perlapine is a potent full agonist of hM3Dq and does not activate hM3. CNO (compound **5a**) was used as a positive control in the hM3Dq FLIPR assay, and acetylcholine (ACh) was used as a positive control in the hM3 FLIPR assay.](cn-2014-00325v_0003){#fig3}

Conclusion {#sec3}
==========

In summary, we conducted the first SAR studies for hM3Dq, a chemogenetic platform for activating neuronal firing, by the design, synthesis, and pharmacological evaluation of new CNO analogues. We explored multiple regions of the CNO scaffold and observed the following interesting SAR trends: (1) a longer or bulkier *N*-alkyl group as in compounds **4c**, **4d**, **5c**, and **5d** reduces both potency and efficacy for hM3Dq; (2) a basic amino group as in compounds **4a** and **4b** or a permanent positive charge group as in compounds **5a** and **6** is required to retain hM3Dq agonist activity; (3) the negative change on the *N*-oxides such as **5a**--**5d** reduces hM3Dq agonist potency; (4) the 8-chloro group is not required to maintain high agonist potency and efficacy for hM3Dq; and (5) modifications to the benzodiazepine tricyclic core of CNO is tolerated. From these SAR studies, we discovered several compounds such as **13** and **21**, which are very potent full agonists of hM3Dq but do not activate the native human M3 receptor (hM3). In addition, the selectivity of compound **21** against a number of aminergic GPCRs is significantly improved compared with clozapine. Furthermore, we discovered perlapine as a novel, potent hM3Dq agonist, which is \>10 000-fold selective for hM3Dq over hM3. These SAR studies lay the foundation for developing the next generation of DREADD ligands that can selectively activate defined neuronal populations in primates.

Methods {#sec4}
=======

Chemistry {#sec4.1}
---------

### General Methods {#sec4.1.1}

HPLC spectra of all compounds were acquired from an Agilent 6110 Series system with UV detector set to at 220 nm. Samples were injected (5 μL) onto an Agilent Eclipse Plus 4.6 × 50 mm, 1.8 μM, C18 column at room temperature. A linear gradient from 10% to 100% B (MeOH + 0.1% acetic acid) in 5.0 min was followed by pumping 100% B for another 2 min with A being H~2~O + 0.1% acetic acid. The flow rate was 1.0 mL/min. Mass spectra (MS) data were acquired in positive ion mode using an Agilent 6110 single quadrupole mass spectrometer with an electrospray ionization (ESI) source. HRMS analysis was conducted on an Agilent Technologies G1969A high-resolution API-TOF mass spectrometer attached to an Agilent Technologies 1200 HPLC system. Samples were ionized by electrospray ionization (ESI) in positive mode. Nuclear magnetic resonance (NMR) spectra were recorded on a Varian Mercury spectrometer with 400 MHz for proton (^1^H NMR) and 100 MHz for carbon (^13^C NMR); chemical shifts are reported in ppm (δ). Preparative HPLC was performed on Agilent Prep 1200 series with UV detector set to at 220 nm. Samples were injected onto a Phenomenex Luna 75 × 30 mm, 5 μM, C18 column at room temperature. The flow rate was 30 mL/min. Different linear gradient for different compounds were used with A being H~2~O + 0.5% TFA and B being MeOH.

Compounds **2**,^[@ref46],[@ref47]^**3**,^[@ref46],[@ref47]^**4a**,^[@ref46],[@ref47]^**4b**,^[@ref46]^ and **5a**([@ref35],[@ref55]) were prepared according to the procedures described previously.

#### 8-Chloro-11-(4-isopropylpiperazin-1-yl)-5*H*-dibenzo\[*b*,*e*\]\[1,4\]diazepine (**4c**) {#sec4.1.1.1}

A solution of 8,11-dichloro-5*H*-dibenzo\[*b*,*e*\]\[1,4\]diazepine (**3**, 0.397 g, 1.44 mmol) and 1-isopropylpiperazine (1 g, 7.799 mmol) in 1,4-dioxane (20 mL) was stirred overnight at 120 °C. After cooling down, the reaction mixture was concentrated and the residue was dissolved with 50 mL of EtOAc. The resulting solution was washed with 30 mL of aqueous NaHCO~3~. The organic layer was dried over Na~2~SO~4~, and the filtrate was concentrated and the residue was purified by flash column chromatography with 5--10% MeOH in CH~2~Cl~2~ to give the desired product **4c** (0.410 g) in 80% yield: ^1^H NMR (400 MHz, CDCl~3~) δ 7.38--7.16 (m, 2H), 7.04 (d, *J* = 1.5 Hz, 1H), 6.99 (t, *J* = 7.5 Hz, 1H), 6.88--6.72 (m, 2H), 6.58 (d, *J* = 8.3 Hz, 1H), 4.86 (s, 1H), 3.46 (br, s, 4H), 2.70 (quin, *J* = 6.5 Hz, 1H), 2.58 (br s, 4H), 1.06 (d, *J* = 6.5 Hz, 6H). ^13^C NMR (101 MHz,, CDCl~3~) δ 162.84, 152.90, 142.13, 140.59, 132.00, 130.55, 129.24, 126.94, 123.69, 123.18, 123.13, 120.25, 120.15, 54.80 (2C), 48.95 (2C), 47.77, 18.80 (2C). HPLC purity 100%, RT 4.099 min. MS (ESI) 355.2 \[M + H\]^+^. HRMS (ESI) calcd for C~20~H~24~ClN~4~^+^ \[M + H\]^+^: 355.1689. Found: 355.1693.

#### 8-Chloro-11-(4-propylpiperazin-1-yl)-5*H*-dibenzo\[*b*,*e*\]\[1,4\]diazepine (**4d**) {#sec4.1.1.2}

Compound **4d** (0.380 g, 70% yield) was prepared via the same procedure as preparing compound **4c** from 8,11-dichloro-5*H*-dibenzo\[*b*,*e*\]\[1,4\]diazepine (**3**, 0.400 g, 1.52 mmol), 1-propylpiperazine HCl salt (0.500 g, 3.04 mmol), and DIPEA (2 mL, 11.48 mmol) in 1,4-dioxane (20 mL). ^1^H NMR (400 MHz, CDCl~3~) δ 7.31--7.19 (m, 2H), 7.04 (d, *J* = 2.3 Hz, 1H), 6.99 (t, *J* = 7.5 Hz, 1H), 6.79 (dd, *J* = 8.2, 2.0 Hz, 2H), 6.58 (d, *J* = 8.3 Hz, 1H), 4.86 (s, 1H), 3.45 (br s, 4H), 2.50 (br s, 4H), 2.33 (t, *J* = 7.6 Hz, 2H), 1.52 (sixtet, *J* = 7.6 Hz, 2H), 0.90 (t, *J* = 7.3 Hz, 3H). ^13^C NMR (101 MHz, CDCl~3~) δ 162.93, 152.90, 142.08, 140.59, 132.03, 130.52, 129.25, 126.96, 123.69, 123.21, 123.20, 120.26, 120.16, 60.93 (2C), 53.40 (2C), 47.47, 20.21, 12.18. HPLC purity 100%, RT 4.113 min. MS (ESI) 355.2 \[M + H\]^+^. HRMS (ESI) calcd for C~20~H~24~ClN~4~^+^ \[M + H\]^+^: 355.1689. Found: 355.1687.

#### 4-(8-Chloro-5*H*-dibenzo\[*b*,*e*\]\[1,4\]diazepin-11-yl)-1-ethylpiperazine *N*-oxide (**5b**) {#sec4.1.1.3}

A solution of compound **4b** (0.100 g, 0.293 mmol) in CH~2~Cl~2~ (5 mL) was treated with mCPBA (0.064 g, 0.371 mmol) at room temperature. After 10 min, the reaction was completed. The resulting mixture was concentrated and purified by flash column chromatography with 5--15% C (2% NH~4~OH in MeOH) in CH~2~Cl~2~ to give the desired *N*-oxide compound **5b** (0.073 g,) in 70% yield: ^1^H NMR (400 MHz, MeOH-*d*~4~) δ 7.39--7.34 (m, 1H), 7.32 (dd, *J* = 7.8, 1.2 Hz, 1H), 7.05 (t, *J* = 7.5 Hz, 1H), 7.01 (d, *J* = 8.0 Hz, 1H), 6.97 (d, *J* = 2.3 Hz, 1H), 6.87 (dd, *J* = 8.4, 2.4 Hz, 1H), 6.81 (d, *J* = 8.4 Hz, 1H), 3.88 (br s, 2H), 3.74 (t, *J* = 12.1 Hz, 2H), 3.55--3.43 (m, 2H), 3.367 (q, *J* = 7.2 Hz, 2H), 3.19--3.09 (m, 2H), 1.38 (t, *J* = 7.2 Hz, 3H). ^13^C NMR (101 MHz, CDCl~3~) δ 162.06, 153.18, 141.54, 140.62, 132.57, 130.29, 129.35, 126.98, 123.90, 123.56, 122.96, 120.45, 120.43, 66.73 (2C), 63.23 (2C), 42.23, 7.69. HPLC purity 100%, RT 4.394 min. MS (ESI) 357.2 \[M + H\]^+^. HRMS (ESI) calcd for C~19~H~22~ClN~4~O^+^ \[M + H\]^+^: 357.1482. Found: 357.1481.

#### 4-(8-Chloro-5*H*-dibenzo\[*b*,*e*\]\[1,4\]diazepin-11-yl)-1-isopropylpiperazine *N*-oxide (**5c**) {#sec4.1.1.4}

Compound **5c** (0.068 g, 65% yield) was prepared similarly as **5b** from compound **4c** (0.100 g, 0.282 mmol) and mCPBA (0.063 g, 0.365 mmol) in CH~2~Cl~2~ (5 mL). ^1^H NMR (400 MHz, MeOH-*d*~4~) δ 7.39--7.30 (m, 2H), 7.05 (t, *J* = 7.5 Hz, 1H), 7.01 (d, *J* = 7.9 Hz, 1H), 6.97 (d, *J* = 2.3 Hz, 1H), 6.87 (dd, *J* = 8.4, 2.4 Hz, 1H), 6.81 (d, *J* = 8.4 Hz, 1H), 3.90 (br s, 2H), 3.73 (t, *J* = 11.9 Hz, 1H), 3.57--3.40 (m, 3H), 3.19--3.12 (m, 2H), 1.38 (d, *J* = 6.5 Hz, 3H). ^13^C NMR (101 MHz, CDCl~3~) δ 162.02, 153.15, 141.64, 140.61, 132.51, 130.31, 129.38, 126.97, 123.81, 123.55, 123.01, 120.43, 120.39, 70.99 (2C), 60.41 (2C), 42.27, 16.54 (2C). HPLC purity 100%, RT 4.305 min. MS (ESI) 371.2 \[M + H\]^+^. HRMS (ESI) calcd for C~20~H~24~ClN~4~O^+^ \[M + H\]^+^: 371.1639. Found: 371.1642.

#### 4-(8-Chloro-5*H*-dibenzo\[*b*,*e*\]\[1,4\]diazepin-11-yl)-1-propylpiperazine *N*-oxide (**5d**) {#sec4.1.1.5}

Compound **5d** (0.075 g, 72% yield) was prepared using the same procedure as preparing **5b** from compound **4d** (0.100 g, 0.282 mmol) and mCPBA (0.063 g, 0.365 mmol) in CH~2~Cl~2~ (5 mL). ^1^H NMR (400 MHz, MeOH-*d*~4~) δ 7.39--7.34 (m, 1H), 7.32 (dd, *J* = 7.8, 1.2 Hz, 1H), 7.05 (t, *J* = 7.5 Hz, 1H), 7.00 (d, *J* = 8.0 Hz, 1H), 6.97 (d, *J* = 2.3 Hz, 1H), 6.87 (dd, *J* = 8.4, 2.4 Hz, 1H), 6.81 (d, *J* = 8.4 Hz, 1H), 3.86 (br s, 2H), 3.74 (t, *J* = 11.9 Hz, 3H), 3.57--3.44 (m, 2H), 3.29--3.21 (m, 2H), 3.20--3.10 (m, 2H), 2.00--1.84 (m, 2H), 1.00 (t, *J* = 7.4 Hz, 3H); ^13^C NMR (101 MHz, MeOH-*d*~4~) δ 164.31, 155.62, 143.36, 142.96, 133.85, 131.29, 129.72, 127.45, 124.99, 124.29, 124.04, 121.68, 121.53, 73.69 (2C), 64.26 (2C), 43.23, 16.42, 11.37. HPLC purity 100%, RT 4.439 min. MS (ESI) 371.2 \[M + H\]^+^. HRMS (ESI) calcd for C~20~H~24~ClN~4~O^+^ \[M + H\]^+^: 371.1639. Found: 371.1640.

#### 4-(8-Chloro-5*H*-dibenzo\[*b*,*e*\]\[1,4\]diazepin-11-yl)-1,1-dimethylpiperazin-1-ium iodide (**6**) {#sec4.1.1.6}

A solution of **4a** (0.100 g, 0.306 mmol) in acetone (5 mL) was treated with methyl iodide (21 μL, 0.337 mmol) at room temperature. After overnight, the resulting mixture was concentrated, dissolved in 1 mL of MeOH, and diluted with 10 mL of distilled water. The aqueous solution was washed with EtOAc (2 × 10 mL) and concentrated. The residue was purified by preparative HPLC to give the compound **6** (0.079 g) in 55% yield: ^1^H NMR (400 MHz, MeOH-*d*~4~) δ 7.57 (t, *J* = 7.7 Hz, 1H), 7.49 (d, *J* = 7.9 Hz, 1H), 7.26 (d, *J* = 2.3 Hz, 1H), 7.27--7.13 (m, 3H), 7.00 (d, *J* = 8.5 Hz, 1H), 4.03 (br s, 4H), 3.72 (br s, 4H), 3.33 (s, 6H). ^13^C NMR (101 MHz, MeOH-*d*~4~) δ 166.47, 156.55, 145.82, 136.58, 135.26, 132.80, 130.24, 128.46, 126.86, 125.08, 122.75, 122.70, 119.64, 61.86 (2C), 52.46 (2C), 44.44 (2C). HPLC purity 100%, RT 3.893 min. MS (ESI) 341.2 \[M − I\]^+^.

#### 4-(8-Chloro-5*H*-dibenzo\[*b*,*e*\]\[1,4\]diazepin-11-yl)piperazin-2-one (**7**) {#sec4.1.1.7}

A solution of compound **3** (0.200 g, 0.760 mmol) and 2-oxypiperazine (0.152 g, 1.52 mmol) in a 1:1 mixture of 1,4-dioxane and ethanol (15 mL) was stirred overnight at 99 °C. After concentration, the residue was diluted with EtOAc (50 mL) and the solution was washed with 20 mL of aqueous NaHCO~3~. The organic layer was dried over Na~2~SO~4~ and the filtrate was concentrated. The residue was purified by flash column chromatography with 30--50% EtOAc in hexanes to afford the desired product (0.162 g) in 65% yield: ^1^H NMR (400 MHz, CDCl~3~) δ 7.30 (t, *J* = 7.6 Hz, 1H), 7.23 (d, *J* = 7.8 Hz, 1H), 7.05 (s, 1H), 7.02 (t, *J* = 7.6 Hz, 1H), 6.84 (d, *J* = 8.3 Hz, 1H), 6.81 (d, *J* = 7.9 Hz, 1H), 6.60 (d, *J* = 8.3 Hz, 1H), 6.03 (s, 1H), 4.90 (s, 1H), 4.10 (s, 2H), 3.67 (br s, 2H), 3.50 (br s, 2H). ^13^C NMR (101 MHz, CDCl~3~) δ 168.89, 161.84, 153.15, 141.39, 140.49, 132.63, 130.04, 129.37, 127.19, 124.02, 123.52, 122.99, 120.48, 120.39, 51.47, 44.12, 41.15; HPLC purity 100%, RT 4.681 min. MS (ESI) 327.1 \[M + H\]^+^. HRMS (ESI) calcd for C~17~H~16~ClN~4~O^+^ \[M + H\]^+^: 327.1007. Found: 327.1006.

#### 8-(8-Chloro-5*H*-dibenzo\[*b*,*e*\]\[1,4\]diazepin-11-yl)-1,3,8-triazaspiro\[4.5\]decane-2,4-dione (**9**) {#sec4.1.1.8}

A mixture of compound **3** (0.250 g, 0.951 mmol) and commercially available compound **8** (0.200 g, 1.18 mmol) in 20 mL of a mixture of 1,4-dioxane and DMF (2:1) was heated to 130 °C for 24 h. The reaction mixture was cooled down to room temperature and concentrated. The residue was purified by flash column chromatography with 0--10% MeOH in CH~2~Cl~2~ to give the desired product **9** (0.250 g) in 66% yield: ^1^H NMR (400 MHz, CDCl~3~) δ 8.62 (s, 1H), 7.37--7.17 (m, 2H), 7.10--7.03 (m, 2H), 7.01 (t, *J* = 7.5 Hz, 1H), 6.85--6.76 (m, 2H), 6.62 (d, *J* = 8.3 Hz, 1H), 5.06 (s, 1H), 3.90 (br s, 2H), 3.20 (br s, 2H), 2.18--2.05 (m, 2H), 1.74 (s, 2H). ^13^C NMR (101 MHz, CDCl~3~) δ 176.84, 163.26, 156.74, 152.90, 141.62, 140.70, 132.47, 130.29, 129.42, 126.97, 123.82, 123.59, 123.43, 120.48, 62.15 (2C), 43.28, 33.19 (2C). HPLC purity 100%, RT 4.289 min. MS (ESI) 396.1 \[M + H\]^+^. HRMS (ESI) calcd for C~20~H~19~ClN~5~O~2~^+^ \[M + H\]^+^: 396.1222. Found: 396.1221.

#### 4-Amino-1-(8-chloro-5*H*-dibenzo\[*b*,*e*\]\[1,4\]diazepin-11-yl)piperidine-4-carboxylic acid (**10**) {#sec4.1.1.9}

A solution of compound **9** (0.100 g, 0.253 mmol) in 1,2-dimethoxyethane (5 mL) was treated with 5 mL of 0.5 N NaOH at room temperature. The resulting mixture was heated under microwave for 10 min (max power 100 W, max temperature 150 °C, max pressure 17.0 bar). After cooling down to room temperature, the reaction mixture was quenched with 10% citric acid and filtered. The filtrated was purified with preparative HPLC to afford the desired product (0.015 g) in 16% yield: ^1^H NMR (400 MHz, MeOH-*d*~4~) δ 7.63 (t, *J* = 7.7 Hz, 1H), 7.54 (d, *J* = 8.0 Hz, 1H), 7.34 (d, *J* = 19.4 Hz, 1H), 7.25 (t, *J* = 7.9 Hz, 3H), 7.08 (d, *J* = 8.6 Hz, 1H), 4.36--3.59 (m, 4H), 2.70--2.40 (m, 2H), 2.40--2.01 (m, 2H). HPLC purity 100%, RT 3.585 min. MS (ESI) 371.2 \[M + H\]^+^. HRMS (ESI) calcd for C~19~H~20~ClN~4~O~2~^+^ \[M + H\]^+^: 371.1269. Found: 371.1264.

Compound **11** was prepared according to the previously published procedures.^[@ref46]^

#### 1-(4-(8-Chloro-5*H*-dibenzo\[*b*,*e*\]\[1,4\]diazepin-11-yl)piperazin-1-yl)ethanone (**12**) {#sec4.1.1.10}

To the solution of compound **10** (0.400 g, 1.28 mmol) and TEA (0.27 mL, 2.0 mmol) in CH~2~Cl~2~ was added AcCl (0.10 mL, 1.4 mmol) at 0 °C. The resulting mixture was then stirred at 0 °C for 1 h. After removing the solvents, the residue was purified by flash column chromatography with 0--5% MeOH in CH~2~Cl~2~ to give the desired product **12** (0.390 g, 1.10 mmol) in 86% yield: ^1^H NMR (400 MHz, CDCl~3~) δ 7.30 (td, *J* = 7.7, 1.5 Hz, 1H), 7.26--7.22 (m, 1H), 7.04 (d, *J* = 2.4 Hz, 1H), 7.02 (td, *J* = 7.6, 1.0 Hz, 1H), 6.86--6.77 (m, *J* = 2.4 Hz, 2H), 6.60 (d, *J* = 8.3 Hz, 1H), 4.89 (s, 1H), 3.67 (br s, 2H), 3.59--3.46 (m, 4H), 3.34 (br s, 2H), 2.11 (s, *J* = 11.5 Hz, 3H). ^13^C NMR (101 MHz, CDCl~3~) δ 169.41, 162.90, 153.15, 141.57, 140.65, 132.40, 130.20, 129.25, 126.97, 123.75, 123.39, 123.32, 120.42, 120.34, 47.80, 47.26, 46.13, 41.50, 21.62. HPLC purity 100%, RT 4.919 min. MS (ESI) 355.2 \[M + H\]^+^. HRMS (ESI) calcd for C~19~H~20~ClN~4~O^+^ \[M + H\]^+^: 355.1320. Found: 355.1315.

#### 8-Chloro-11-\[4-(1,1-dideutrioethyl)piperazin-1-yl\]-5*H*-dibenzo\[*b*,*e*\]\[1,4\]diazepine (**13**) {#sec4.1.1.11}

To the solution of compound **12** (0.100 g, 0.282 mmol) in 15 mL of anhydrous THF was added LiAlD~4~ (0.024 g, 0.572 mmol) at room temperature under N~2~ atmosphere. The reaction mixture was heated under reflux conditions for 2 h. The reaction was quenched with 0.1 mL of CD~3~OD at 0 °C. The resulting mixture was treated with 0.5 mL of NH~4~OH at 0 °C and filtered through Celite and the filtrate was concentrated. The residue was purified by flash column chromatography with 0--10% MeOH in CH~2~Cl~2~ to give the desired product **13** (0.081 g) in 84% yield: ^1^H NMR (400 MHz, CDCl~3~) δ 7.33--7.23 (m, 3H), 7.06 (d, *J* = 2.4 Hz, 1H), 7.01 (td, *J* = 7.6, 1.0 Hz, 1H), 6.81 (dd, *J* = 8.3, 2.4 Hz, 2H), 6.60 (d, *J* = 8.3 Hz, 1H), 4.88 (s, 1H), 3.49 (br, s, 4H), 2.54 (br, s, 4H), 1.10 (s, 3H); ^13^C NMR (101 MHz, CDCl~3~) δ 162.90, 152.87, 142.03, 140.59, 132.02, 130.46, 129.17, 126.91, 123.60, 123.17, 120.24, 120.16, 52.87 (2C), 51.78 (q, *J* = 20.0 Hz), 47.44, 11.86 (2C). HPLC purity 100%, RT 4.072 min; MS (ESI) 343.2 \[M+1\]^+^. HRMS (ESI) calcd for C~19~H~20~D~2~ClN~4~^+^ \[M + H\]^+^: 343.1653. Found: 343.1653.

#### 8-Chloro-11-(4-(methylsulfonyl)piperazin-1-yl)-5*H*-dibenzo\[*b*,*e*\]\[1,4\]diazepine (**14**) {#sec4.1.1.12}

To a solution of compound **11** (0.102 g, 0.326 mmol) and DIPEA (87 μL, 0.907 mmol) in 10 mL of CH~2~Cl~2~, MsCl (27.8 μL, 0.359 mmol) was added at 0 °C. After 1 h, the reaction was completed. The reaction mixture was diluted with 50 mL of CH~2~Cl~2~ and washed with 10 mL of aqueous NaHCO~3~. The organic layer was dried over Na~2~SO~4~, and the filtrate was concentrated and the residue was purified by flash column chromatography with 50% EtOAc in hexanes to give the desired product **14** (0.118 g) in 93% yield: ^1^H NMR (400 MHz, CDCl~3~) δ 7.31 (t, *J* = 7.7 Hz, 1H), 7.22 (d, *J* = 7.8 Hz, 1H), 7.08--6.96 (m, 2H), 6.87--6.78 (m, 2H), 6.61 (d, *J* = 8.3 Hz, 1H), 4.90 (s, 1H), 3.57 (br s, 4H), 3.29 (br s, 4H), 2.79 (s, 3H). ^13^C NMR (101 MHz, DMSO-*d*~6~) δ 162.44, 154.11, 142.23, 141.48, 132.24, 129.80, 126.69, 125.58, 122.88, 122.64, 122.40, 120.69, 120.40, 46.33, 45.14 (2C), 33.85 (2C). HPLC purity 100%, RT 4.752 min. MS (ESI) 391.1 \[M + H\]^+^. HRMS (ESI) calcd for C~18~H~20~ClN~4~O~2~S^+^ \[M + H\]^+^: 391.0990. Found: 391.0994.

Compounds **17**--**21** were prepared according to the previously reported procedures.^[@ref48]^

#### 11-(Piperazin-1-yl)-5*H*-dibenzo\[*b*,*e*\]\[1,4\]diazepine (**21**) {#sec4.1.1.13}

^1^H NMR (400 MHz, MeOH-*d*~4~) δ 7.39--7.24 (m, 1H), 7.06--6.95 (m, 3H), 6.94--6.82 (m, 3H), 3.34 (br s, 1H), 2.96--2.85 (m, 2H). ^13^C NMR (101 MHz, MeOH-*d*~4~) δ 165.39, 156.04, 145.04, 141.55, 133.31, 131.47, 127.85, 125.34, 124.88, 124.66, 123.78, 121.26, 120.71, 46.47. HPLC purity 99%, RT 2.772 min. MS (ESI) 279.2 \[M+1\]^+^. HRMS (ESI) calcd for C~17~H~19~N~4~^+^ \[M + H\]^+^: 279.1604. Found: 279.1610.

#### 11-(4-Ethylpiperazin-1-yl)-5*H*-dibenzo\[*b*,*e*\]\[1,4\]diazepine (**22**) {#sec4.1.1.14}

A solution of compound **20** (0.420 g, 1.84 mmol) and 1-ethylpiperazine (1.5 mL, 11.81 mmol) in toluene (20 mL) was heated under reflux conditions for 2 h. After cooling down to room temperature and concentration, the residue was purified by flash column chromatography with 0--10% MeOH in CH~2~Cl~2~ to give the desired product **22** (0.409 g) in 72% yield: ^1^H NMR (400 MHz, CDCl~3~) δ 7.30--7.18 (m, 2H), 7.06 (dd, *J* = 7.8, 1.5 Hz, 1H), 7.00--6.90 (m, 2H), 6.84 (tt, *J* = 7.3, 3.7 Hz, 1H), 6.80 (dd, *J* = 7.4, 1.1 Hz, 1H), 6.67 (dd, *J* = 7.7, 1.4 Hz, 1H), 4.89 (s, 1H), 3.45 (br s, 4H), 2.53 (br s, 4H), 2.46 (q, *J* = 7.2 Hz, 2H), 1.10 (t, *J* = 7.2 Hz, 3H). ^13^C NMR (101 MHz, CDCl~3~) δ 162.52, 153.35, 141.97, 140.73, 131.82, 130.54, 127.40, 124.46, 123.86, 123.82, 122.93, 120.16, 119.48, 53.06 (2C), 52.65 (2C), 47.56, 12.18. HPLC purity 100%, RT 3.122 min. MS (ESI) 307.2 \[M + H\]^+^. HRMS (ESI) calcd for C~19~H~23~N~4~^+^ \[M + H\]^+^: 307.1917. Found: 307.1918.

#### 4-(5*H*-Dibenzo\[*b*,*e*\]\[1,4\]diazepin-11-yl)-1-ethylpiperazine *N*-oxide (**23**) {#sec4.1.1.15}

A solution of compound **22** (0.095 g, 0.31 mmol) in CH~2~Cl~2~ (10 mL) was treated with mCPBA (0.069 g) at room temperature. After 10 min, the reaction mixture was concentrated and the residue was purified with 0--10% C (5% NH~4~OH in MeOH) in CH~2~Cl~2~ to afford the desired product **23** (0.078 g) in 78% yield: ^1^H NMR (400 MHz, MeOH-*d*~4~) δ 7.39--7.29 (m, 2H), 7.07--6.97 (m, 3H), 6.96--6.82 (m, 3H), 3.84 (br s, 2H), 3.79--3.66 (m, 2H), 3.56--3.43 (m, 2H), 3.35 (q, *J* = 7.0 Hz, 2H), 3.18--3.07 (m, 2H), 1.37 (t, *J* = 7.1 Hz, 3H). ^13^C NMR (101 MHz, MeOH-*d*~4~) δ 163.66, 155.93, 144.50, 141.44, 133.64, 131.23, 127.98, 125.69, 125.05, 124.16, 124.13, 121.44, 120.80, 66.90 (2C), 63.79 (2C), 43.32, 7.70. HPLC purity 100%, RT 3.312 min. MS (ESI) 323.2 \[M + H\]^+^. HRMS (ESI) calcd for C~19~H~23~N~4~O^+^ \[M + H\]^+^: 323.1866. Found: 323.1863.

Biological Assays {#sec4.2}
-----------------

hM3Dq and hM3 FLIPR assays were performed according to the protocols reported previously.^[@ref11],[@ref50],[@ref51]^ Protocols for 5-HT~2A~, 5-HT~2C~, α~1A~, and H~1~ radioligand binding assays are available at the National Institute of Mental Health--Psychoactive Drug Screening Program Web site (<http://pdsp.med.unc.edu/UNC-CH%20Protocol%20Book.pdf>).
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